Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of CKD-388 (Tenofovir Alafenamide) in Healthy Subjects
NCT05189288Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jan 2022
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tenofovir alafenamide in Chronic Hepatitis B (CHB) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Curve to the last measurable concentration at 72 hours and Maximum Plasma Concentration at 72 hours. Started Jan 2022; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05189288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05189288.